Hikma Pharmaceuticals Share News (HIK)
HIK Share
HIK Share
HIK Share
HIK Share
HIK
HIK Share
HIK Level 2
HIK Live
HIK Broker
HIK Directors
HIK Financial
HIK
HIK Short
HIK
Last checked at -
Mon, 11th Nov 2013 17:07
LONDON (Alliance News) - Hikma Pharmaceuticals PLC Monday said that Michael Raya, president and chief executive of the US, sold 12,200 shares at GBP12.06 pence per share.
Raya holds a total of 44,384 shares in total, representing a 0.02% stake.
Hikma Pharmaceutical shares closed up 0.6% Monday, at 1,204.42 pence per share.
By Rowena Harris-Doughty; rowenaharrisdoughty@alliancenews.com; @rharrisdoughty
Copyright © 2013 Alliance News Limited. All Rights Reserved.
LONDON BROKER RATINGS: Peel Hunt ups InterContinental Hotels to Hold
Read moreLONDON BRIEFING: Softbank's Fortress doesn't give up on Morrisons
Read more
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* UK employment closer to pre-pandemic levels* BHP Group jumps on strong results* PLUS500 gains on robust revenue forecasts* FTSE 100 up 0.3%...
Read moreLONDON MARKET CLOSE: FTSE 100 boosted by strong US jobs report
Read moreLONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls
Read moreLONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near
Read moreTOP NEWS: Hikma hikes Generics guidance as interim profit swells
Read moreLONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance
Read more
(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance for its generics arm and reported a rise in first-half profit and revenue as it hailed a strong performance in both the generics and branded segments, and resilience in the injectables business.
Read moreUK earnings, trading statements calendar - next 7 days
Read moreIN BRIEF: Arecor ends first half of 2021 with solid cash position
Read moreBROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight
Read moreBROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart
Read more(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...
Read more
Last checked at